结合人口学特征比较国产和原研伊马替尼治疗慢性髓性白血病慢性期患者的有效性和安全性

OBJECTIVES: To compare the efficacy and safety of Chinese generic imatinib with branded imatinib as frontline therapy in adults with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) (Frontline group) , and to explore the efficacy and safety of Chinese generic imatinib in CML-CP pat...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial office of Chinese Journal of Hematology 2019
Materias:
论著
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342368/
https://www.ncbi.nlm.nih.gov/pubmed/31856442
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2019.11.008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342368/
https://www.ncbi.nlm.nih.gov/pubmed/31856442
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2019.11.008

Ejemplares similares